Product image of Icalziss (Calcium Chloride Dihydrate) supplied by GNH India

Icalziss

Active Ingredient:
Calcium Chloride Dihydrate
Origin:
EU

Icalziss (Calcium Chloride Dihydrate)

Calcium chloride dihydrate, the active ingredient in Icalziss, is an excipient (calcium salt) presented as a solution for injection for extracorporeal use. It is employed to restore extracellular calcium levels in patients with hypocalcemia and as a component of intravenous electrolyte solutions.

GNH India supplies Icalziss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide, adhering to EU GMP standards and providing validated cold‑chain logistics for injectable products. The company offers regulatory documentation, batch release certificates, and responsive technical support to ensure seamless integration into clinical pharmacy inventories.

Manufacturer / TM Owner

Vantive Belgium

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Icalziss provides calcium ions to address disorders of calcium deficiency and is used in intravenous electrolyte management.

  • Hypocalcemia: restores low serum calcium levels, helping prevent cardiac and neuromuscular complications.
  • Intravenous electrolyte solutions: serves as a calcium source in balanced IV fluid formulations for perioperative and critical care patients.
  • Calcium supplementation during renal replacement therapy: supplies calcium needed to maintain circuit stability and patient calcium balance.

How It Works

  • Calcium chloride dihydrate dissociates in plasma to release calcium ions (Ca²⁺). The liberated calcium directly increases extracellular calcium concentration, correcting hypocalcemia. By providing readily bioavailable calcium, it supports calcium‑dependent physiological processes such as cardiac contractility, neurotransmission, and coagulation cascade activation. The solution is administered intravenously, allowing rapid distribution throughout the vascular compartment.

Side Effects

Adverse reactions to Icalziss are generally related to the rapid increase of serum calcium and the properties of the injectable solution.

Common Side Effects

  • Injection site pain: mild discomfort at the site of administration.
  • Phlebitis: inflammation of the vein used for infusion.
  • Hypercalcemia symptoms: transient nausea, headache, or dizziness.
  • Electrolyte imbalance: transient shifts in magnesium or phosphate levels.

Serious or Rare Side Effects

  • Cardiac arrhythmias: potentially life‑threatening rhythm disturbances.
  • Tissue necrosis: severe extravasation causing local tissue damage.
  • Severe allergic reaction: anaphylaxis, though extremely uncommon.

Precautions & Warnings

When using Icalziss, clinicians should observe specific precautions to minimize risks and ensure product integrity.

  • Verify serum calcium: confirm hypocalcemia and baseline calcium levels before administration.
  • Infuse slowly: administer via controlled infusion to avoid rapid calcium spikes.
  • Monitor cardiac function: continuous ECG monitoring is recommended during infusion.
  • Assess renal function: impaired kidneys may reduce calcium clearance.
  • Avoid concurrent calcium‑containing medications: prevent additive calcium load.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Calcium chloride can interact with several drugs, altering their efficacy or safety profile.

Major Interactions (Avoid)

  • Digoxin: increased risk of digoxin toxicity due to calcium‑mediated effects on cardiac conduction.
  • Calcium channel blockers: additive hypotensive effect; monitor blood pressure closely.

Moderate Interactions (Monitor Closely)

  • Loop diuretics (e.g., furosemide): may increase calcium excretion, requiring calcium level monitoring.
  • Bisphosphonates: concurrent use can cause hypocalcemia; ensure adequate calcium supplementation.
  • Antacids containing aluminum or magnesium: may reduce calcium absorption if given orally, though less relevant for IV use.
  • Magnesium sulfate: concurrent high doses can precipitate calcium‑magnesium complexes.

Frequently Asked Questions

Icalziss is an injectable solution of calcium chloride dihydrate used to correct low blood calcium levels (hypocalcemia) and to provide calcium as part of balanced intravenous electrolyte formulations in hospitals and critical‑care settings.

When administered intravenously, calcium chloride dihydrate dissociates into calcium ions, rapidly raising extracellular calcium concentration. This restores normal calcium‑dependent cellular functions such as cardiac contractility, nerve transmission, and blood clotting.

The dose of Icalziss is determined by the prescribing clinician based on the patient’s serum calcium level, clinical condition, and weight. Healthcare professionals calculate the appropriate volume and infusion rate for each individual case.

Safety data for calcium chloride dihydrate injection in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Icalziss, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Icalziss delivers calcium as calcium chloride, which provides a higher proportion of free calcium ions compared with calcium gluconate or calcium carbonate. This results in a faster rise in serum calcium, making it suitable for acute correction, whereas oral supplements are generally used for chronic maintenance.

Icalziss must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Before use, inspect the vial for particulate matter and ensure the solution is at room temperature if required by the administration protocol.

Icalziss is given by intravenous injection or infusion. The exact route (bolus or controlled infusion) and rate are determined by the prescriber, who considers the severity of hypocalcemia and the patient’s cardiovascular status.

Serious risks include rapid development of hypercalcemia leading to cardiac arrhythmias, severe tissue necrosis from extravasation, and rare anaphylactic reactions. Continuous cardiac monitoring and careful infusion technique help mitigate these hazards.

Icalziss should be avoided in patients with known hypersensitivity to calcium chloride, severe hypercalcemia, uncontrolled ventricular arrhythmias, or those receiving incompatible intravenous solutions that could precipitate calcium salts.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Calcium Chloride Dihydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT